Axonics ModulationTechnologies Inc

Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women. The company was founded by Raymond W. Cohen, Guang Qiang Jiang, and Danny L. Dearen in March 2012 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Axonics reports record Q4 revenue, eyes global expansion opportunities

Axonics Modulation Technologies Inc delivered strong financial performance in Q4 2022, with record revenue, solid margins, and profitability, while reiterating revenue guidance for 2023.
The company's focus on innovation, market leadership in sacral neuromodulation, and global expansion plans position it well for future growth despite challenges in international markets and legal uncertainties.
Opportunities in the U.S. and Asian markets, coupled with strategic initiatives like direct-to-consumer campaigns and product enhancements, offer avenues for sustained revenue growth and market dominance.

Axonics reports robust Q1 earnings, eyes market expansion opportunities

Axonics Modulation Technologies Inc delivered strong financial performance in Q1 2023, driven by revenue growth, operational efficiency, and strategic guidance updates for FY 2023.
The company's strengths lie in its robust commercial team, successful marketing campaigns, focus on innovation, and leadership's commitment to disciplined growth strategies.
While facing challenges such as legal uncertainties, coverage limitations, and margin management, Axonics has opportunities for market expansion, acquisitions, and technology advancements.
Overall, Axonics' performance, strengths, challenges, and opportunities position the company for continued growth and market leadership in the neuromodulation industry.

Axonics Modulation Technologies Reports Record Q2 Revenue Growth

Axonics Modulation Technologies delivered a strong performance in Q2, driven by revenue growth and operational efficiency.
The company's strengths lie in international expansion, robust commercial efforts, and continuous product innovation.
Challenges include legal uncertainties, market dynamics, and strategic positioning in a competitive landscape.
Opportunities for growth include market expansion, rising adoption trends, and enhancing customer experience.

Axonics reports robust Q3 earnings, eyes growth through innovation

Axonics delivered strong financial performance, driven by SNM and Bulkamid revenue growth and improved margins.
The company's focus on innovation, customer feedback, and market leadership positions it well for future growth.
Challenges include maintaining growth momentum, high rep productivity, and balancing marketing strategies.
Opportunities lie in expanding product offerings, market share, and leveraging direct-to-consumer campaigns for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axonics, Inc. (NASDAQ:AXNX ) Q2 2023 Earnings Conference Call July 27, 2023 4:30 PM ET Company Participants Neil Bhalodkar - Vice President of Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Polark - Wolfe Research Shagun Singh - RBC Capital Markets Operator That today's conference is being recorded. I would now like to hand the conference over to your speaker today, Neil Bhalodkar.

Axonics, Inc. (AXNX) Q2 2023 Earnings Call Transcript

Axonics Modulation Technologies (AXNX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.47 per share a year ago.

Axonics Modulation Technologies (AXNX) Reports Q2 Loss, Tops Revenue Estimates

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended June 30, 2023. “Our commercial team continues to execute at a high level, generating revenue growth of 35% year over year in the second quarter,” said Raymond W. Cohen, chief executive officer. “Our growth was driven by higher utiliza.

Axonics Reports Second Quarter 2023 Financial Results

Apple

Asana

Butterfly Network

Celsius Holdings

Cisco Systems

D.R. Horton

Enphase Energy

Intel

Jiayin Group Inc - ADR

JPMorgan Chase & Co

Coca-Cola

Microsoft

NIKE

Procter & Gamble

Super Micro Computer

UnitedHealth Group

Two new Breakout Stocks for Week 29 with better than 10% short-term upside and a Dow 30 Pick. Average cumulative returns for 2023 are at +126.4% YTD. Last week 3 out of 4 picks gained over 13.4% with peak gains in KODK +23.8%, SMCI +19.2%, YMM +13.4%. The S&P 500 gained +2.4%. The streak of weekly picks gaining over 10% in less than a week has reached 254 out of 320 trading weeks (79.3%) not considering multiple gainers or negative MG signals.

July MDA Breakout Stocks Week 29 - 2023: High-Frequency Gainers To Give You An Edge

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2023 financial results after the close of trading on Thursday, July 27. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. To access the conference call by telephone, interested parties may register at the following link: Axon.

Axonics to Report Second Quarter 2023 Financial Results on July 27

Axonics is under pressure after Q1 results came in solid but guidance didn't increase as much as hoped. The company has 2 solid products and the medical technology space has performed well recently.

Axonics: Q1 Fall Provides Great Entry Point

Axonics, Inc. (NASDAQ:AXNX ) Q1 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Neil Bhalodkar - VP of IR Raymond Cohen - CEO Dan Dearen - President and CFO Conference Call Participants Chris Pasquale - Nephron Research Richard Newitter - Truist Securities Nathan Treyback - Wells Fargo Adam Maeder - Piper Sandler Michael Polark - Wolfe Research Shagun Singh - RBC Capital Markets Mike Matson - Needham and Company Anthony Petrone - Mizuho Securities Michael Sarcone - Jefferies Operator Thank you for standing by and welcome to the Axonics' First Quarter 2023 Results Conference Call. At this time, all participants are in listen-only mode.

Axonics, Inc. (AXNX) Q1 2023 Earnings Call Transcript

Axonics Modulation Technologies (AXNX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago.

Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2023. “Our commercial team continues to execute at a high level, generating revenue growth of 46% year over year in the first quarter,” said Raymond W. Cohen, chief executive officer. “Our sacral neuromodulation growth was d.

Axonics Reports First Quarter 2023 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following upcoming investor conferences: Event: BofA Securities Healthcare Conference Date: Tuesday, May 9 Time: 2:20 p.m. Eastern Time Event: RBC Capital Markets Healthcare Conference Date: Tuesday, May 16 Time: 4:05 p.m. Eastern Time Interested parties may.

Axonics to Participate in Upcoming Investor Conferences

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the acquisition of a lead placement solution from Radian, LLC that complements Axonics' existing sacral neuromodulation (SNM) offering. Physicians determine a patient's eligibility for long-term SNM therapy by performing an external trial or peripheral nerve evaluation (PNE). T.

Axonics Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral Neuromodulation

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report first quarter 2023 financial results after the close of trading on Monday, May 1. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results.

Axonics to Report First Quarter 2023 Financial Results on May 1

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it ranked No. 2 on the Financial Times 2023 list of the fastest growing companies in the Americas. This follows the company's No. 1 ranking on the 2022 list. Companies were ranked based on the compound annual growth rate of their revenue from 2018 to 2021.

Axonics Ranked No. 2 on the Financial Times 2023 List of the Fastest Growing Companies in the Americas

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is participating as a platinum sponsor of the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2023 Winter Meeting, which is being held in Nashville from March 7-11.

Axonics to Participate in the SUFU 2023 Winter Meeting

Axonics, Inc. (NASDAQ:AXNX ) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Neil Bhalodkar - VP of IR Raymond Cohen - CEO Dan Dearen - President and CFO Conference Call Participants Travis Steed - Bank of America Larry Biegelsen - Wells Fargo Chris Pasquale - Nephron Research Cecilia Furlong - Morgan Stanley David Rescott - Truist Adam Maeder - Piper Sandler Michael Polark - Wolfe Research Shagun Singh - RBC Capital Markets Michael Sarcone - Jefferies Mike Matson - Needham and Company Operator Good day and thank you for standing by. Welcome to Axonics' Fourth Quarter 2022 Results Conference Call.

Axonics, Inc. (AXNX) Q4 2022 Earnings Call Transcript

Axonics (AXNX) delivered earnings and revenue surprises of 104.35% and 0.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Axonics Modulation Technologies (AXNX) Surpasses Q4 Earnings and Revenue Estimates

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2022. “This quarter's record results reflect the growing demand for our best-in-class incontinence products,” said Raymond W. Cohen, chief executive officer of Axonics. “Our U.S.

Axonics Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Axonics (AXNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Axonics (AXNX) Might Surprise This Earnings Season

Axonics (AXNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Axonics Modulation Technologies (AXNX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter 2022 financial results after the close of trading on Wednesday, March 1. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results.

Axonics to Report Fourth Quarter 2022 Financial Results on March 1

IRVINE, Calif.--( BUSINESS WIRE )--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration has approved the company's fourth-generation rechargeable sacral neuromodulation system.

Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Axonics (AXNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Axonics (AXNX) Soars 10.6%: Is Further Upside Left in the Stock?

Axonics, Inc. AXNX shares are trading higher after the company reported preliminary fourth-quarter and full-year 2022 total net revenue results above estimates. The company also issued FY23 revenue guidance above estimates.

Why Axonics Shares Are Trading Higher Today? - Axonics (NASDAQ:AXNX)

IRVINE, Calif.--( BUSINESS WIRE )--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited revenue for the fiscal year ended December 31, 2022 and issued fiscal year 2023 revenue guidance.

Axonics Reports Preliminary Fiscal Year 2022 Revenue and Provides Fiscal Year 2023 Revenue Guidance

Anavex Life Sciences

MannKind

Neurocrine Biosciences

Cassava Sciences Inc

Vertex Pharmaceuticals

Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's a six-pack of favorite biotech ideas for the coming year.

News for Axonics ModulationTechnologies Inc Stock (AXNX)